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The conventional method for quantification of Chlamydia infection using fluorescence microscopy typically involves time- and
labor-intensive manual enumeration, which is not applicable for a large-scale analysis required for an inhibitory compound
screen. In this study, an alamarBlue (resazurin) assay was adopted to measure Chlamydia infection by measuring the redox ca-
pability of infected host cells in a 96-well format. The assay provided measurements comparable to those of the conventional
microscopy method while drastically reducing the time required for analysis.
The development of new classes of antimicrobial agents is im-perative due to the increasing resistance of pathogenic bacteria
to existing antibiotics and its growing threat to public health.
Among these organisms, Chlamydia trachomatis is the causative
agent for the most common bacterial sexually transmitted infec-
tion in the United States (1). The unique biology of Chlamydia as
an obligate intracellular organism presents challenges to identify-
ing novel compounds against the organism. The standard tech-
nique for quantification of Chlamydia infection is the immuno-
fluorescence assay (IFA), which relies on visual detection of
fluorescently stained bacteria and host cells. This process is labor-
intensive and not suitable for large-scale screening required for
antimicrobial compound development. Effective methods for large-
scale, image-based quantification have been reported for Chlamydia
infection (2–4). However, automation of image acquisition typi-
cally requires specialized equipment and extensive computational
resources. Therefore, development of a facile and accurate
method would be beneficial for screening potential antichlamyd-
ial compounds.
alamarBlue (resazurin) is a colorimetric cell viability indicator
widely used to monitor eukaryotic cell proliferative activity (5).
The redox dye resazurin enters the cytosol in the oxidized form
(blue) and is converted to the reduced form, resorufin (red). The
reduced and oxidized forms of alamarBlue can be separately mea-
sured by a spectrophotometer and used to determine the reduc-
tion capability of cells, which reflects the status of mitochondrial
function and cell viability. One significant advantage of alamar-
Blue over other metabolic indicators is that the compound allows
continuous monitoring of cells (6). This is due to the fact that the
compound does not interfere with the activity of the respiratory
chain and, therefore, is nontoxic to the cells. alamarBlue has found
applications in quantitative analysis of cell viability (7), prolifera-
tion (8), cytotoxicity (9), and drug susceptibility (10, 11) in both
bacterial and eukaryotic systems as well as high-throughput
screening of antimicrobial compounds in microorganisms such as
Mycobacterium tuberculosis (12) and Staphylococcus aureus (13).
In this study, the alamarBlue assay was adapted for enumeration
of C. trachomatis infection by measuring the lysis of infected host
cells as indicated by a decrease in cell viability. To demonstrate the
ability of this assay to measure anti-Chlamydia activity, infections
in the presence of the well-established anti-Chlamydia com-
pounds tetracycline and polymyxin B were enumerated.
A productive developmental cycle of C. trachomatis strain L2
typically takes 48 to 72 h and is completed with the host cell lysis or
extrusion (14). In order to correlate the infection level with the
host cell viability, we first determined a time point where the lysis
of infected host cells results in a significant decrease of the overall
host cell viability among the samples. In addition, to validate this
method as an effective enumeration tool for Chlamydia infection,
sensitivity of the assay was examined by analyzing samples in-
fected with a 2-fold dilution of Chlamydia elementary body (EB).
The parallel samples were also prepared and analyzed by the con-
ventional IFA for comparison. L929 mouse fibroblast cells in a
96-well tissue culture plate (BD Bioscience, Billerica, MA) were
infected with C. trachomatis lymphogranuloma venereum (LGV)
L2/434/Bu elementary bodies diluted in Hanks’ balanced salt so-
lution (HBSS; Mediatech, Inc., Manassas, VA). Following a 2-h
inoculation at room temperature, the inoculum was removed,
RPMI 1640 tissue culture medium (Mediatech, Inc.) was supple-
mented with 5% fetal bovine serum (Thermo Fisher Scientific,
Liverpool, NY), and 10 g/ml gentamicin (MP Biomedicals, Santa
Ana, CA) was added. At 24, 48, and 72 h postinfection (hpi),
alamarBlue (Invitrogen, Grand Island, NY) was diluted in tissue
culture medium without phenol red to a final concentration of
10% and added to the cells. The reducing capability of the infected
cells was monitored by measuring absorbance at 570 nm (re-
duced) and 600 nm (oxidized) using a PowerWave microplate
spectrophotometer equipped with KC4 data collection/analysis
software (BioTek Instruments, Inc., Winooski, VT) and reported
as a percentage relative to the mock-infected sample, using the
following formula provided by the manufacturer: ([εox]2A1 
[εox]1A2)/([εox]2A=1  [εox]1A=2)  100, where εox is the
molar extinction coefficient of the alamarBlue oxidized form, the
numerator is the test agent, the denominator is the untreated con-
trol, A is the absorbance of the test wells, A= is the absorbance of
the positive-control well (mock infection), 1 is 570 nm, and 2 is
600 nm.
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Table 1 summarizes the reducing capability of infected samples
as well as the infection level determined by IFA. To statistically
compare and evaluate the data sets, the Z= factor was determined.
The Z= factor is a statistical parameter used to evaluate the quality
of high-throughput assays, where Z= factor values greater than 0.5
are indicative of excellent low variation and signal dynamic range
(15). At 24 hpi, the reduction capability of the infected sample was
mostly comparable to that of mock-infected cells with the excep-
tion of the three highest inoculation doses (1:1, 1:2, and 1:4 dilu-
tions). Given that cell lysis upon completion of the developmental
cycle takes place 48 to 72 hpi, this decrease at the high inoculation
doses is likely to be a result of cytotoxicity due to overinfection
rather than completion of the developmental cycle. At 48 and 72
hpi, the expected dose-dependent decrease in reduction capability
was observed to range from 108.17 to 6.90% and 105.87 to 4.21%,
respectively, over increasing inoculation doses. The Z= factor for
48-hpi analysis was determined to be above 0.5 for the three high-
est inoculation doses, which corresponds to 95.77 to 90.64% in-
fection reported by IFA. When infection was allowed to proceed
for an additional 24 h, the 7 highest inoculation doses, corre-
sponding to 95.77 to 20.8% infection levels, resulted in a Z= factor
greater than 0.5, indicating that the analysis in this infection range
can be performed with a high degree of confidence at 72 hpi. In
order to utilize this assay in measuring infection level or assessing
anti-Chlamydia activity of compounds, a sufficient dynamic range
must be provided, and therefore, 72 hpi was chosen as the time
point for the subsequent analysis. In addition, when a correlation
coefficient (R2) was used to determine the degree of similarity
between the two methods, linear regression analysis between the
data sets obtained from the alamarBlue assay (72 hpi) and IFA
resulted in a correlation coefficient of 0.98, indicating a strong
correlation between the two analyses and further supporting that
enumeration of Chlamydia infection by the alamarBlue assay is
highly comparable to results with the conventional IFA.
To begin validating this method as an anti-Chlamydia com-
pound screening tool, inhibition of C. trachomatis infection by
two well-established inhibitors, tetracycline hydrochloride (USB
Corporation, Cleveland, OH) and polymyxin B sulfate (PMB;
Enzo Life Science, New York, NY), was assessed (16–18). Tetracy-
cline is membrane permeant and inhibits bacterial translation,
whereas PMB primarily affects surface molecules (lipopolysaccha-
ride [LPS]/lipooligosaccharide [LOS]) on bacteria and negatively
perturbs membrane integrity. Chlamydia infection was per-
formed as described above to achieve approximately 90% infec-




24 hpi in IFA
Reducing capability of infected cells relative to the mock-infected cellsa
24 hpi 48 hpi 72 hpi
Avg (%) SD (%) Z= factor Avg (%) SD (%) Z= factor Avg (%) SD (%) Z= factor
1:1 95.77 26.40 1.36 0.56* 6.90 0.68 0.83* 4.21 0.08 0.98*
1:2 92.94 61.80 3.66 0.02 18.83 0.89 0.79* 6.13 0.28 0.97*
1:4 90.64 87.84 4.71 2.47 46.35 0.27 0.72* 13.42 1.59 0.92*
1:8 86.70 103.00 6.16 14.50 69.27 0.78 0.47 27.96 2.17 0.88*
1:16 63.95 107.29 2.15 3.74 85.86 2.26 0.47 49.17 2.91 0.79*
1:32 43.61 109.90 5.82 3.60 96.11 1.15 3.50 74.03 2.82 0.60*
1:64 20.80 114.35 4.43 1.88 106.17 0.42 1.48 85.67 1.35 0.57*
1:128 14.79 119.60 9.48 1.88 99.23 5.43 38.28 88.67 2.00 0.29
1:256 7.20 114.30 0.77 1.13 102.47 0.49 5.27 100.06 0.72 75.83
1:512 3.06 108.15 8.51 5.58 105.74 0.61 1.76 100.58 0.47 4.98
1:1,024 2.16 102.65 4.24 14.41 103.46 1.90 4.71 102.67 2.49 2.57
1:2,048 1.08 120.76 8.34 1.56 108.26 0.66 0.94 103.06 0.50 0.17
1:4,096 0.98 109.81 0.48 2.01 108.17 2.61 1.67 105.87 0.66 0.31
R2 0.52 0.79 0.98
a Z= factors of 1 and 0.5 (marked with asterisks) are indicative of an assay with suitable screening characteristics (14). SD, standard deviation.
FIG 1 Dose-dependent inhibition of C. trachomatis infection (72 hpi) by
polymyxin B (A) or tetracycline (B). Error bars indicate standard deviations of
the triplicate infections.
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tion in the untreated control sample. For PMB treatment, purified
C. trachomatis cells were diluted in HBSS containing a 2-fold di-
lution of PMB ranging from 0.02 to 1.28 g/ml and incubated for
an hour prior to proceeding to infection as described previously
(17). For tetracycline treatment, tissue culture medium contain-
ing various concentrations of the compound ranging from 0.10 to
0.70 g/ml was added to the cells following EB inoculation. In
both PMB- and tetracycline-treated samples, the compound con-
centration and reduction capability of infected cells resulted in a
positive linear correlation, with R2 values of 0.97 and 0.99, respec-
tively (Fig. 1). For tetracycline, a concentration range above 0.50
g/ml was not included in determining this linear regression since
the inhibition plateaued at 0.50 g/ml. Importantly, the plateau of
the reduction capability of infected cells at this concentration is
consistent with a previously reported observation by IFA that 0.51
g/ml was sufficient to achieve 100% inhibition of C. trachomatis
serovar L2 (19). Furthermore, no significant effect on the reduc-
tion capability was observed when cells were incubated with anti-
biotics alone (data not shown).
Together, these data demonstrate that measuring host cell vi-
ability of infected cells can be used as an indirect enumeration of
Chlamydia infection, as it reflected the infection level determined
by the conventional IFA. Although the method requires a 72-hour
incubation time, the high-throughput capacity of a microplate
reader considerably reduces the active time required for analysis.
While further studies are clearly required, this method may pro-
vide a rapid and cost-effective approach to the discovery of novel
anti-Chlamydia compounds with the added benefit of dual func-
tion (i.e., host-cell toxicity analysis and Chlamydia inhibitory
properties).
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